Plain-English Summary
STEP 5 extends the semaglutide obesity evidence window to two years, showing sustained weight-loss benefit while treatment continues.
VV Study Evidence Matrix v1.0
VV Evidence Utility Score
A bounded score for how useful this study is in public explanation, based on evidence tier, design, applicability, endpoint relevance, limitations, safety signals, and publication/source strength.
75/100
Useful Public Evidence
- Evidence tier
- 78/100, weight 18%
- Design strength
- 89/100, weight 18%
- Applicability
- 75/100, weight 16%
- Endpoint relevance
- 68/100, weight 16%
- Limitations transparency
- 70/100, weight 12%
- Safety signal usefulness
- 45/100, weight 10%
- Publication/source strength
- 88/100, weight 10%
Useful for context, but limited by safety signal usefulness, endpoint relevance, limitations transparency.
How the study framework works ->Key Findings
- Semaglutide produced sustained mean weight loss over 104 weeks compared with placebo.
- The trial supports the idea that continued treatment can maintain large weight loss beyond the 68-week STEP 1 time horizon.
- Improvements in waist circumference and cardiometabolic risk markers were directionally consistent with sustained weight reduction.
- Gastrointestinal adverse events remained an important tolerability signal.
Limitations
- STEP 5 was much smaller than STEP 1, so it is less definitive for less common events or subgroup claims.
- The study still does not answer what happens after discontinuation at two years.
- Trial monitoring and lifestyle support may not match routine consumer use.
Why It Matters
It helps the site avoid treating STEP 1 as a one-off short-term result and gives stronger support for claims about persistence of effect under continued treatment.
Viral Vitalism Verdict
Good longer-duration efficacy evidence, but still not a free pass on long-term strategy, adverse effects, real-world adherence, or what happens when treatment stops.
Sources
- Two-year effects of semaglutide in adults with overweight or obesity - Nature Medicine
Signal cards
Used in signals
Signal coverage connected to this study through explicit study links, canonical source refs, or evidence visualizations.
GLP-1s Are Not Just a Weight Loss Story
GLP-1 medications are being studied for effects that may extend beyond weight loss, including cardiometabolic outcomes and behavior-related pathways.
VV Signal Score
76
Promising signal
- Sources
- 31
- Studies
- 11
- Claims
- 16
Claim ledger
Relevant claims
Claim ledger records connected through this study's ID, topic tags, or source IDs.
semaglutide: Semaglutide reduced major adverse cardiovascular events in SELECT participants
Semaglutide reduced major adverse cardiovascular events in SELECT participants with overweight or obesity and established cardiovascular disease without diabetes.
semaglutide: Semaglutide reduced body weight in adults with obesity or
Semaglutide reduced body weight in adults with obesity or overweight in randomized clinical-trial populations.
glp 1: Semaglutide and tirzepatide should not be collapsed into one
Semaglutide and tirzepatide should not be collapsed into one generic claim because their mechanisms, labels, trial programs, and outcome evidence differ.
glp 1: Semaglutide and tirzepatide produce clinically meaningful average weight loss
Semaglutide and tirzepatide produce clinically meaningful average weight loss in studied adults with obesity or overweight, with results and tolerability varying by drug, dose, and patient context.
glp 1: FDA-approved GLP-1 products and compounded, unapproved, or falsely labeled
FDA-approved GLP-1 products and compounded, unapproved, or falsely labeled products are different regulatory and quality-risk categories.
weight loss: Sustained fat loss requires net energy deficit, but the
Sustained fat loss requires net energy deficit, but the appetite, expenditure, adaptation, and maintenance systems that shape that deficit are biologically regulated.